Net Cash Provided by (Used in) Financing Activities of VERTEX PHARMACEUTICALS INC / MA from 31 Mar 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
VERTEX PHARMACEUTICALS INC / MA annual and quarterly Net Cash Provided by (Used in) Financing Activities in USD history and change rate from 31 Mar 2010 to 31 Dec 2025.
  • VERTEX PHARMACEUTICALS INC / MA Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $680,400,000, a 90% decline year-over-year.
  • VERTEX PHARMACEUTICALS INC / MA annual Net Cash Provided by (Used in) Financing Activities for 2025 was $2,261,300,000, a 51% decline from 2024.
  • VERTEX PHARMACEUTICALS INC / MA annual Net Cash Provided by (Used in) Financing Activities for 2024 was $1,494,900,000, a 166% decline from 2023.
  • VERTEX PHARMACEUTICALS INC / MA annual Net Cash Provided by (Used in) Financing Activities for 2023 was $562,200,000, a 730% decline from 2022.
Source SEC data
View on sec.gov
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)

VERTEX PHARMACEUTICALS INC / MA Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $2,261,300,000 -$766,400,000 -51% 01 Jan 2025 31 Dec 2025 10-K 13 Feb 2026 2025 FY
2024 $1,494,900,000 -$932,700,000 -166% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2026 2025 FY
2023 $562,200,000 -$494,500,000 -730% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2026 2025 FY
2022 $67,700,000 +$1,410,300,000 +95% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 $1,478,000,000 -$972,700,000 -192% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 $505,300,000 -$632,100,000 -499% 01 Jan 2020 31 Dec 2020 10-K 10 Feb 2023 2022 FY
2019 $126,800,000 +$198,019,000 01 Jan 2019 31 Dec 2019 10-K 09 Feb 2022 2021 FY
2018 $71,219,000 -$139,623,000 -204% 01 Jan 2018 31 Dec 2018 10-K 11 Feb 2021 2020 FY
2017 $68,404,000 -$64,867,000 -49% 01 Jan 2017 31 Dec 2017 10-K 13 Feb 2020 2019 FY
2016 $133,271,000 -$55,648,000 -29% 01 Jan 2016 31 Dec 2016 10-K 13 Feb 2019 2018 FY
2015 $188,919,000 01 Jan 2015 31 Dec 2015 10-K 15 Feb 2018 2017 FY
2010 $425,057,000 01 Jan 2010 31 Dec 2010 10-K 17 Feb 2011 2010 FY

VERTEX PHARMACEUTICALS INC / MA Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $680,400,000 -$322,900,000 -90% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q1 2024 $357,500,000 -$62,800,000 -21% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q1 2023 $294,700,000 -$199,300,000 -209% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q1 2022 $95,400,000 +$423,300,000 +82% 01 Jan 2022 31 Mar 2022 10-Q 02 May 2023 2023 Q1
Q1 2021 $518,700,000 -$159,270,000 -44% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q1 2020 $359,430,000 -$317,441,000 -756% 01 Jan 2020 31 Mar 2020 10-Q 30 Apr 2021 2021 Q1
Q1 2019 $41,989,000 -$120,945,000 -153% 01 Jan 2019 31 Mar 2019 10-Q 01 May 2020 2020 Q1
Q1 2018 $78,956,000 +$368,521,000 01 Jan 2018 31 Mar 2018 10-Q 01 May 2019 2019 Q1
Q1 2017 $289,565,000 -$294,267,000 -6258% 01 Jan 2017 31 Mar 2017 10-Q 27 Apr 2018 2018 Q1
Q1 2016 $4,702,000 -$45,712,000 -91% 01 Jan 2016 31 Mar 2016 10-Q 28 Apr 2017 2017 Q1
Q1 2015 $50,414,000 01 Jan 2015 31 Mar 2015 10-Q 03 May 2016 2016 Q1
Q1 2011 $16,357,000 -$23,999,000 -314% 01 Jan 2011 31 Mar 2011 10-Q 06 May 2011 2011 Q1
Q1 2010 $7,642,000 01 Jan 2010 31 Mar 2010 10-Q 06 May 2011 2011 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.